ClinicalTrials.gg
RecruitingNCT06910579Updated Oct 15, 2026

Oxygenated Gel Therapy in the Management of Oral Aphthous Ulcers

A Phase 2/3 interventional study of topical application of oxygenated gel and topical application of Triamcinolone acetonide gel in Aphthus Ulcer, sponsored by British University In Egypt. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by British University In Egypt · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Ulcer with a site in Egypt — 3 open to participants now, 3 under way, 1 of them phase 3. Ulcer · Egypt.

Planned enrollment
12th of 20
30 · median 38
Started
2025
with 1 other
Phase 2/3
Only one
of the 22
Registered
18th of 22
by date
Lead sponsor
1 of 22
British University In Egypt

Among the 22 studies in Ulcer with a site in Egypt, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2/3, and was the 18th registered.

Ulcer

360 studies on the registry are indexed under Ulcer; 61 are open to participants now.

Browse Ulcer studies →

Open to participants now

3 of the 22 studies in Ulcer with a site in Egypt are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Ulcer with a site in Egypt, or all of them as a file.
02

Study summary

Interventions of both groups:

Oxygenated gel Group: 15 patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days.

Triamcinolone acetonide Group: 15 patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.

Patients in both groups were reexamined after treatment at different intervals (day 3, day 5, day 7, and day 10).

03

Conditions studied

  • Aphthus Ulcer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically diagnosed patients with chronic aphthous stomatitis measuring ≤6 mm in size in the oral cavity and who gave written consent for participation.
  • Only single ulcers were considered for the study.
  • Systemically healthy patients.

Exclusion criteria

Exclusion Criteria:

  • The study excluded patients with a history of associated systemic disease.
  • Cases of chronic aphthous stomatitis (major), lesions of herpetic form, numerous aphthae, and smoking.
  • Patients with a history of to the used agents.
  • Pregnancy and lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    control

    15 patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.

    Drug: topical application of Triamcinolone acetonide gel

  • Experimental
    Oxygenated gel Group

    15 patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days

    Drug: topical application of oxygenated gel

Interventions

  • Drugtopical application of oxygenated gel

    patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days

  • Drugtopical application of Triamcinolone acetonide gel

    patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Visual Analog Scale (0-10), which measured a range of "no pain" to "unbearable pain" on a 100 mm horizontal line \[10\]. to determine the intensity of pain on day 0, day 3, day 5, day 7, and day 10

    Time frame: 10 days

Secondary outcomes

  1. Size of ulcers (in mm)

    after starting treatment, ulcer size was recorded on day 0, day 3, day 5, day 7, and day 10 using a calibrated dental probe with millimeter marking

    Time frame: 10 days

  2. Complete healing duration

    the duration till complete healing is achieved is recorded in days

    Time frame: 10 days

  3. OHIP-14

    has been assessed 1 week after intervention. OHIP-14 utilizes a scale with five categories (1 = never, 2 = hardly ever, 3 = occasionally, 4 = fairly often, and 5 = very often). A lower score in any of the five categories indicates higher satisfaction

    Time frame: 10 days

07

Study locations

1 of 1 sites recruiting
  • British University in Egypt
    Al Sherouk City, Cairo Governorate 11837, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication will be shared

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2026 → Jan 2027 and completion Apr 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Mar 15, 2025
Primary completionEst.
Jan 30, 2027was Jan 2026
CompletionEst.
Jul 12, 2027was Apr 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 30, 2026→Jan 30, 2027
Oct 15, 2026
Study completion
Apr 12, 2026→Jul 12, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Jan 30, 2026→Jan 30, 2027
    Study completion Apr 12, 2026→Jul 12, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06910579
Lead sponsor
British University In Egypt
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Mar 15, 2025
Primary completion
Jan 30, 2027 (estimated)
Completion
Jul 12, 2027 (estimated)
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion